VERA
Vera Therapeutics Inc - Ordinary Shares - Class A

1,364
Mkt Cap
$1.83B
Volume
865,190.00
52W High
$51.27
52W Low
$18.53
PE Ratio
-7.16
VERA Fundamentals
Price
$27.85
Prev Close
$28.55
Open
$29.05
50D MA
$28.23
Beta
1.03
Avg. Volume
1.11M
EPS (Annual)
-$2.75
P/B
4.57
Rev/Employee
$0.00
Loading...
Loading...
News
all
press releases
Vera Therapeutics, Inc. (NASDAQ:VERA) Receives Average Recommendation of "Moderate Buy" from Analysts
Vera Therapeutics, Inc. (NASDAQ:VERA - Get Free Report) has been given a consensus rating of "Moderate Buy" by the eleven brokerages that are covering the company, Marketbeat reports. One investment...
MarketBeat·4d ago
News Placeholder
More News
News Placeholder
Candriam S.C.A. Has $7 Million Stock Holdings in Vera Therapeutics, Inc. $VERA
Candriam S.C.A. decreased its position in Vera Therapeutics, Inc. (NASDAQ:VERA - Free Report) by 18.4% during the 2nd quarter, according to the company in its most recent filing with the SEC. The...
MarketBeat·4d ago
News Placeholder
Vera Therapeutics (NASDAQ:VERA) SVP Joseph Young Sells 15,000 Shares
Vera Therapeutics, Inc. (NASDAQ:VERA - Get Free Report) SVP Joseph Young sold 15,000 shares of the stock in a transaction that occurred on Tuesday, November 11th. The shares were sold at an average...
MarketBeat·5d ago
News Placeholder
Insider Selling: Vera Therapeutics (NASDAQ:VERA) SVP Sells 15,000 Shares of Stock
Vera Therapeutics, Inc. (NASDAQ:VERA - Get Free Report) SVP Joseph Young sold 15,000 shares of the firm's stock in a transaction dated Tuesday, November 11th. The stock was sold at an average price...
MarketBeat·6d ago
News Placeholder
Quinn Opportunity Partners LLC Buys Shares of 19,000 Vera Therapeutics, Inc. $VERA
Quinn Opportunity Partners LLC purchased a new stake in shares of Vera Therapeutics, Inc. (NASDAQ:VERA - Free Report) in the second quarter, according to its most recent 13F filing with the...
MarketBeat·6d ago
News Placeholder
Vera Therapeutics (NASDAQ:VERA) Shares Gap Up Following Analyst Upgrade
Vera Therapeutics (NASDAQ:VERA) Shares Gap Up After Analyst Upgrade...
MarketBeat·9d ago
News Placeholder
Vera Therapeutics (NASDAQ:VERA) Price Target Raised to $90.00
HC Wainwright boosted their target price on Vera Therapeutics from $85.00 to $90.00 and gave the stock a "buy" rating in a research report on Monday...
MarketBeat·9d ago
News Placeholder
FY2025 EPS Estimates for VERA Decreased by Lifesci Capital
Vera Therapeutics, Inc. (NASDAQ:VERA - Free Report) - Research analysts at Lifesci Capital decreased their FY2025 EPS estimates for shares of Vera Therapeutics in a research note issued on Wednesday...
MarketBeat·11d ago
News Placeholder
Vera Therapeutics (NASDAQ:VERA) Given New $52.00 Price Target at JPMorgan Chase & Co.
JPMorgan Chase & Co. reduced their price target on Vera Therapeutics from $53.00 to $52.00 and set an "overweight" rating for the company in a research report on Friday...
MarketBeat·12d ago
News Placeholder
Vera Therapeutics Submits BLA For Atacicept In IgA Nephropathy
(RTTNews) - Vera Therapeutics Inc. (VERA) announced the submission of a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for atacicept, its investigational therapy...
Nasdaq News: Markets·13d ago

Latest VERA News

View

Advertisement|Remove ads.

Advertisement|Remove ads.